First breakthrough in treating asthma attacks and COPD in 50 years hailed as a ‘game-changer’ by doctors - Benralizumab is a monoclonal antibody that targets specific white blood cells, called ...

Eosinophilic gastroenteritis (EGE) is characterized by dense eosinophilic inflammation of one or several digestive tract sections. The symptoms include abdominal pain, weight loss, vomiting and ...

First new treatment for asthma attacks in 50 years is 30 per cent more effective than steroid tablets, UK scientists find ...

The first new asthma attack treatment for 50 years has been hailed as a potential "game-changer", scientists have said.

Eosinophils are pro-inflammatory white blood cells thought to protect against parasitic infections, but in excessive numbers they can cause tissue and organ damage, as observed in eosinophilic ...

An injection given during some asthma and COPD attacks is more effective than the current treatment of steroid tablets, ...

First described nearly 20 years ago, eosinophilic esophagitis (EoE) is an inflammatory disease of the esophagus characterized by eosinophilic infiltration of the esophageal epithelium. Over 50% of ...

An injection given during some asthma and COPD attacks is more effective than the current treatment of steroid tablets, ...

A clinical trial of the drug benralizumab showed it was far more effective than conventional steroid tablets at treating life-threatening breathing difficulties in people with a severe form of the ...

King’s College, London researchers say they have found the first new treatment for asthma attacks in 50 years. Benralizumab ...

Benralizumab, a monoclonal antibody, is the first breakthrough in asthma and COPD flare-up treatment in 50 years. Targeting ...

Eupraxia Pharmaceuticals' shares rose after the clinical-stage biotechnology company reported positive data from its Eosinophilic Esophagitis program, which it believes underscore its DiffuSphere ...